Author:
Won Eunsoo,Han Kyu-Man,Kim Aram,Lee Min-Soo,Kim Yong-Ku,Chang Hun Soo,Ham Byung-Joo
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,General Pharmacology, Toxicology and Pharmaceutics,Toxicology,Pathology and Forensic Medicine
Reference40 articles.
1. Hirschfeld, R. M. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry
61 Suppl 6, 4–6 (2000).
2. Massart, R., Mongeau, R. & Lanfumey, L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Philos Trans R Soc Lond B Biol Sci
367, 2485–2494, doi:
https://doi.org/10.1098/rstb.2012.0212
(2012).
3. Kramer, M. S. et al. Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology
29, 385–392, doi:
https://doi.org/10.1038/sj.npp.1300260
(2004).
4. Hafizi, S., Chandra, P. & Cowen, J. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations. Br
J Psychiatry 191, 282–284, doi:10.1192/bjp.bp.107.037879 (2007).
5. Ebner, K. & Singewald, N. The role of substance P in stress and anxiety responses. Amino Acids
31, 251–272, doi:
https://doi.org/10.1007/s00726-006-0335-9
(2006).